Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14+
SponsorUniversity of California, Davis

About this trial

The main purpose of this stepped wedge trial will be to test the impact of a bundle of implementation strategies designed to improve ED-outpatient care coordination on long-term buprenorphine retention among adult patients who start buprenorphine for opioid use disorder in a hospital emergency department (ED) and then are referred for continued outpatient buprenorphine treatment after they leave the ED. Our hypothesis is that adopting the bundle of implementation strategies will be associated with subsequent increases in:

A) Cumulative number of days with active buprenorphine prescription at 3, 6, and 12 months after patients' initial ED visit (6 months = primary outcome)

B) Proportion of patients with active buprenorphine prescriptions without gaps in buprenorphine coverage of more than 7 days at 3, 6, and 12 months after patients' initial ED visit

C) Proportion of patients who fill at least 1 outpatient buprenorphine prescription within 30 days of their ED visit

D) Clinician reported quality of ED-outpatient care coordination and care transitions

Eligibility criteria

Qualifiers

patients who start buprenorphine for opioid use disorder at a participating ED

Disqualifiers

None

Trial design

Treatments tested in this trial

  • care coordination implementation strategies

Treatment groups

3,492 Participants
are divided into 1 treatment group

Locations

4
El Centro Regional Medical Center Emergency Department92243, El CentroCalifornia, United States
University of California Irvine Emergency Department92868, IrvineCalifornia, United States
Marshall Medical Center Emergency Department95667, PlacervilleCalifornia, United States
University of California Davis Emergency Department95817, SacramentoCalifornia, United States

Sponsors and collaborators

University of California, Davis

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator